(Q36844715)

16 August 2017

1 reference

title

The perfect mix: recent progress in adjuvant research (English)

1 reference

16 August 2017

Bruno Guy

1

1 reference

PubMed ID

17558426

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Nature Reviews Microbiology

16 August 2017

1 reference

16 August 2017

5

1 reference

16 August 2017

505-517

1 reference

16 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrmicro1681

16 August 2017

0 references

cites work

Vaccine manufacturing: challenges and solutions

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Overview of vaccine adjuvants: present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

DAMPs, PAMPs and alarmins: all we need to know about danger

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

The expanding universe of T-cell subsets: Th1, Th2 and more.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Expanding the effector CD4 T-cell repertoire: the Th17 lineage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Natural regulatory T cells in infectious disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Understanding the generation and function of memory T cell subsets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Translating innate immunity into immunological memory: implications for vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Co-stimulatory agonists as immunological adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptor control of the adaptive immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-dependent selection of microbial antigens for presentation by dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptor stimulation as a third signal required for activation of human naive B cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Control of B-cell responses by Toll-like receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Immunology: Toll-like receptors and antibody responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptor 2 controls expansion and function of regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-dependent control mechanisms of CD4 T cell activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Intracellular pattern recognition receptors in the host response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Nod-like proteins in immunity, inflammation and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

5'-Triphosphate RNA is the ligand for RIG-I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Scavenger receptors in innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Myeloid C-type lectins in innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Yin-Yang regulation of autoimmunity by DCs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

The TREM receptor family and signal integration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Gammadelta T cells: an alternative type of professional APC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

How bacteria and their products provide clues to vaccine and adjuvant development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptors as adjuvant receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Taking toll: lipid A mimetics as adjuvants and immunomodulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Cooperation of Toll-like receptor signals in innate immune defence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Mechanisms of stimulation of the immune response by aluminum adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Promotion of B cell immune responses via an alum-induced myeloid cell population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

ISCOM-based vaccines: the second decade.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Liposomes as protein carriers in immunology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Microparticles as vaccine adjuvants and delivery systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Targeting dendritic cells with biomaterials: developing the next generation of vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

New tools for antigen delivery to the MHC class I pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Towards the rational design of Th1 adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Therapeutic potential of Toll-like receptor 9 activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Inducing and expanding regulatory T cell populations by foreign antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Restoring function in exhausted CD8 T cells during chronic viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Therapeutic vaccination in chronic hepatitis B virus carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Entry of microbes into the host: using M cells to break the mucosal barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Targeting polymerised liposome vaccine carriers to intestinal M cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Regulatory considerations on new adjuvants and delivery systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptors in systemic autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

CTLA4Ig: bridging the basic immunology with clinical application

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

31 March 2020

Lessons from TGN1412.

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Of mice and not men: differences between mouse and human immunology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Effect of priming on subsequent response to inactivated influenza vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Maturation of dendritic cells by bacterial immunomodulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

TLR4 is the signaling but not the lipopolysaccharide uptake receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Immunological foundations to the quest for new vaccine adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

Herpes simplex virus type 2 vaccines: new ground for optimism?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1681

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRMICRO1681

1 reference

16 August 2017

1 reference

PubMed ID

17558426